ArticleWorld journal of surgical oncology2005
Aberrant E-cadherin staining patterns in invasive mammary carcinoma.
Article in World journal of surgical oncology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 30 citations in OpenAlex.
- Article
- Lobular Breast Cancer: Histomorphology and Different Concepts of a Special Spectrum of Tumors.Cancers · 2021Review
- Primary Signet Ring Cell/Histiocytoid Carcinoma of the Eyelid: Somatic Mutations inCurrent oncology (Toronto, Ont.) · 2021Article
- E-cadherin clone 36 nuclear staining dictates adverse disease outcome in lobular breast cancer patients.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2019Article
- Characteristics of the Epithelial-Mesenchymal Transition in Primary and Paired Metastatic Canine Mammary Carcinomas.Veterinary pathology · 2018Article
- Lobular Carcinoma In Situ.Surgical pathology clinics · 2018Review
- E-cadherin expression as a prognostic factor in patients with ovarian cancer: a meta-analysis.Oncotarget · 2017Article
- Aberrant P-cadherin expression is associated to aggressive feline mammary carcinomas.BMC veterinary research · 2014Article
- Clonal relatedness between lobular carcinoma in situ and synchronous malignant lesions.Breast cancer research : BCR · 2012Article
- ADAM33 gene silencing by promoter hypermethylation as a molecular marker in breast invasive lobular carcinoma.BMC cancer · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundE-cadherin, a cell surface protein involved in cell adhesion, is present in normal breast epithelium, benign breast lesions, and in breast carcinoma. Alterations in the gene CDH1 on chromosome 16q22 are associated with changes in E-cadherin protein expression and function. Inactivation of E-cadherin in lobular carcinomas and certain diffuse gastric carcinomas may play a role in the dispersed, discohesive "single cell" growth patterns seen in these tumors. The molecular "signature" of mammary lobular carcinomas is the loss of E-cadherin protein expression as evidenced by immunohistochemistry, whereas ductal carcinomas are typically E-cadherin positive. PATIENTS AND
methodsWe report on E-cadherin immunostaining patterns in five cases of invasive mammary carcinoma.
resultsThese were five exceptional instances in which the E-cadherin immunophenotype did not correspond to the apparent histologic classification of the lesion. These cases which are exceedingly rare in our experience are the subject of this report.
conclusionFindings such as those illustrated in this study occur in virtually all biologic phenomena and they do not invalidate the very high degree of correlation between the expression of E-cadherin and the classification of breast carcinomas as ductal or lobular type on the basis of conventional histologic criteria.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.